

Syngene launches platform for rapid, enhanced protein production

05 June 2024 | News

Enabling quicker preclinical and clinical development as well as product launches



Bengaluru-based Syngene International, a leading global contract research, development and manufacturing organization (CRDMO), has announced the launch of its new protein production platform.

The platform, using a cell line and transposon-based technology in-licensed from Swiss biotech services company, ExcellGene, coupled with Syngene's clone selection and development processes, promises significant improvement in efficiency and precision.

The new platform accelerates enhanced protein production, enabling quicker preclinical and clinical development as well as product launches, thereby reducing time to market.

The new platform streamlines clone selection and enhances operational productivity. It also supports a wide range of biomolecules including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates and other recombinant proteins. This versatility facilitates integration with both perfusion and fed-batch manufacturing processes.

A track record in developing multiple monoclonal antibodies with the new technology underscores its effectiveness and reinforces Syngene's ability to provide innovative solutions for its clients. By combining this technology with Syngene's existing capabilities, the company now offers a full range of end-to-end cell line development options, using the latest technology to deliver tangible benefits to customers.

"By combining the cell line and transposon-based platform from ExcellGene with our proprietary processes, we are pushing the boundaries in cell line development. This innovative approach will not only accelerate development timelines but also enhance the overall reliability and efficiency of the process, delivering substantial benefits to our clients," said Sridevi Khambampaty, Vice President, Biopharmaceutical Development, Syngene International.